IDH2 and astrocytoma (excluding glioblastoma): This might be of relevance to assure sufficient tumor cell content for correct evaluation of deletions, e.g. the distinction of homozygous from hemizygous CDKN2A deletion in an IDH-mutant astrocytoma.